As part of our continued development of Histologix services we are pleased to announce that the reading of all future GLP-compliant therapeutic antibody cross-reactivity studies will be undertaken by a British (FRCPath), American (DiplACVP) board-certified veterinary and toxicologic histopathologist.
With an extensive track record of evaluating a range of therapeutic antibody molecules and lending this histopathology experience to an already successful service we believe will enhance the quality of the service even further.
Histologix Ltd has been offering cross-reactivity studies since its inception in 2005 although its Directors were instrumental in developing the first recognised regulatory-compliant cross-reactivity screening service in 1989 and having presented those protocols to the FDA in 1992, they have since become an industry standard and the basis for current study designs.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.